>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance:
  • CLNS -22.8%, PTLA -17.3%, BOX -14.2%, WPP -11.9%, CCRN -11.2%, PDCO -10.4%,MNST -7.8%, BLDP -7.8%, EPR -6.4%, LB -6.2%, HLIT -5.8%, HK -4.1%, CODI -3.9%,RVNC -3.9%, (Revance Therapeutics and Mylan (MYL) announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX), KTOS -3.3%, (Kratos Defense and Security executes definitive agreement to sell Public Safety and Security divisions to Securitas Eletronic Security for approx $70 mln; KTOS will be reporting earnings shortly), ITCI -3.1%, LOXO -2.9%, PEGI -2.5%, PF -2.5%, PEIX -2.4%, CPG -2.1%,AMBC -1.9%, BSTI -1.8%, BGNE -1.3%, IPXL -1.2%, CBPO -1.1%, GEF -1%
Other news:
  • OSTK -10.3% (discloses in regulatory filing that the SEC is investigating its tZERO unit)
  • ATRA -6% (prices offering of 4,285,714 shares of its common stock at $35.00 per share)
  • SFUN -4.7% (lower on block trade pricing)
  • CORI -3.1% (announces proposed offering of $100 mln of convertible senior notes, provides update on fda feedback on pilot bioequivalence study )
  • SC -2.4% (indicated lower after filing its 10-K disclosing it received Civil Investigative Demands in August)
  • AST -2.3% (provides additional data from the company's ongoing Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of AST-OPC1 in the treatment of severe cervical spinal cord injury)
  • CCI -2% (Crown Castle commences offering of 7,765,000 shares of common stock pursuant to an effective shelf registration statement )
  • GDDY -1.7% (announces public offering of 16,916,000 shares of Class A common stock by stockholders pursuant to an effective Registration Statement), AGN -1.4% (notified by the FDA that the review of the New Drug Application for ulipristal acetate will be extended)
  • FCAU -1.3% (Fiat Chrysler says reviewing potential separation of Magneti Marelli in the second quarter of 2018 )
  • HLNE -1% (prices 3.94 mln shares of common stock at $34.25 per share)
Analyst comments:
  • CPB -1.7% (downgraded to Underweight from Neutral at Piper Jaffray)